Literature DB >> 18054414

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Kazutoyo Miura1, Andrew C Orcutt, Olga V Muratova, Louis H Miller, Allan Saul, Carole A Long.   

Abstract

Enzyme linked immunosorbent assay (ELISA) has been widely used to measure antibody titers for evaluating the immunogenicity of a vaccine. However, there is as yet no generally accepted way of expressing the ELISA results in the case of experimental vaccines, since there is usually no uniform standard. Both end point and single dilution methods have significant disadvantages. In this paper, we obtained reproducible data with fewer dilutions of samples by addition of serially diluted standard serum to each ELISA plate. Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054414      PMCID: PMC2253722          DOI: 10.1016/j.vaccine.2007.10.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Increased coating efficiency of antigens and preservation of original antigenic structure after coating in ELISA.

Authors:  T Jitsukawa; S Nakajima; I Sugawara; H Watanabe
Journal:  J Immunol Methods       Date:  1989-01-17       Impact factor: 2.303

2.  Enhanced ELISA: how to measure less than 10 picograms of a specific protein (immunoglobulin) in less than 8 hours.

Authors:  E Macy; M Kemeny; A Saxon
Journal:  FASEB J       Date:  1988-11       Impact factor: 5.191

3.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Authors:  Elissa M Malkin; Anna P Durbin; David J Diemert; Jetsumon Sattabongkot; Yimin Wu; Kazutoyo Miura; Carole A Long; Lynn Lambert; Aaron P Miles; Jin Wang; Anthony Stowers; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

4.  Comparison of an ELISA system for the quantification of hepatitis B antibody with an automated and a semi-automated system.

Authors:  V A Player; D White
Journal:  J Virol Methods       Date:  1993-11       Impact factor: 2.014

Review 5.  Enzyme immunoassays with special reference to ELISA techniques.

Authors:  A Voller; A Bartlett; D E Bidwell
Journal:  J Clin Pathol       Date:  1978-06       Impact factor: 3.411

6.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

Authors:  Aaron P Miles; Yanling Zhang; Allan Saul; Anthony W Stowers
Journal:  Protein Expr Purif       Date:  2002-06       Impact factor: 1.650

8.  Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials.

Authors:  Lanling Zou; Aaron P Miles; Jin Wang; Anthony W Stowers
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

9.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

10.  Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.

Authors:  Elissa Malkin; Carole A Long; Anthony W Stowers; Lanling Zou; Sanjay Singh; Nicholas J MacDonald; David L Narum; Aaron P Miles; Andrew C Orcutt; Olga Muratova; Samuel E Moretz; Hong Zhou; Ababacar Diouf; Michael Fay; Eveline Tierney; Philip Leese; Siddhartha Mahanty; Louis H Miller; Allan Saul; Laura B Martin
Journal:  PLoS Clin Trials       Date:  2007-04-06
View more
  128 in total

1.  Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Gregory Tullo; Samuel E Moretz; Joan A Aebig; Michael P Fay; Louis H Miller; Ogobara K Doumbo; Issaka Sagara; Alassane Dicko; Carole A Long; Ruth D Ellis
Journal:  Vaccine       Date:  2011-01-31       Impact factor: 3.641

2.  Antigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malaria.

Authors:  Lester H Lambert; Jeanee L Bullock; Sharma T Cook; Kazutoyo Miura; David N Garboczi; Mahamadou Diakite; Rick M Fairhurst; Kavita Singh; Carole A Long
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.

Authors:  Chiawei W Tsai; Peter F Duggan; Albert J Jin; Nicholas J Macdonald; Svetlana Kotova; Jacob Lebowitz; Darrell E Hurt; Richard L Shimp; Lynn Lambert; Louis H Miller; Carole A Long; Allan Saul; David L Narum
Journal:  Mol Biochem Parasitol       Date:  2008-11-27       Impact factor: 1.759

4.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

5.  Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.

Authors:  Kazutoyo Miura; Eizo Takashima; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Daria Nikolaeva; Mahamadou Diakite; Rick M Fairhurst; Michael P Fay; Carole A Long; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

6.  Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

Authors:  Feng Qian; Joan A Aebig; Karine Reiter; Emma Barnafo; Yanling Zhang; Richard L Shimp; Kelly M Rausch; David S Jones; Daming Zhu; Lynn Lambert; Gregory E D Mullen; David L Narum; Louis H Miller; Yimin Wu
Journal:  Microbes Infect       Date:  2008-12-27       Impact factor: 2.700

7.  Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Authors:  Kazutoyo Miura; Raul Herrera; Ababacar Diouf; Hong Zhou; Jianbing Mu; Zonghui Hu; Nicholas J MacDonald; Karine Reiter; Vu Nguyen; Richard L Shimp; Kavita Singh; David L Narum; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

8.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

9.  VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.

Authors:  Justin Yai Alamou Doritchamou; Raul Herrera; Joan A Aebig; Robert Morrison; Vu Nguyen; Karine Reiter; Richard L Shimp; Nicholas J MacDonald; David L Narum; Michal Fried; Patrick E Duffy
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

10.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.